Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stemcells, Inc. to Feature at 2011 World Stem Cell Summit

Published: Monday, October 03, 2011
Last Updated: Sunday, October 02, 2011
Bookmark and Share
Speakers to address the science, technology and clinical development of the Company’s human neural stem cell platform.

StemCells, Inc. has announced that three of its senior executives and a key academic research collaborator are scheduled to present at the 2011 World Stem Cell Summit scheduled for October 3-5, 2011 at the Pasadena Convention Center, Pasadena, California.

The World Stem Cell Summit is the global stem cell and regenerative medicine community’s leading event, and allows scientists, patients, advocates, business people, investors, educators, ethicists, policy makers, and government representatives from around the world to meet, share knowledge and collaborate with others in the field.

Ann Tsukamoto, Ph.D., Executive Vice President, Research & Development of StemCells, Inc., will be a featured speaker during a plenary discussion on “How Stem Cells Are Transforming Medicine - ISSCR Perspectives,” which is scheduled for 9:00 am PT on Monday, October 3.

Aileen Anderson, Ph.D., a professor at the University of California, Irvine, will speak during a session on “Stem Cell Translational Report - Spinal Cord Injury, Paralysis and MS,” which is scheduled to begin at 2:30 pm PT on Tuesday, October 4.

Dr. Anderson has collaborated with the Company to publish numerous preclinical studies to demonstrate the therapeutic potential of the Company’s human neural stem cells for the treatment of spinal cord injury.

Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. will be a featured speaker during a session on “Promising Science from Industry Labs.” This session is scheduled to begin at 1:00 pm PT on Wednesday, October 5.

Martin McGlynn, President and CEO of StemCells, Inc., will discuss the Company’s clinical development program during a session on “Key Clinical Trial Updates,” which is scheduled to begin at 2:00 pm PT on Wednesday, October 5.

The Company is currently conducting two clinical trials of its HuCNS-SC® cells, one in chronic spinal cord injury and one in a myelination disorder in the brain.

The multiple presentations by the Company’s executives and collaborator highlight the scientific achievements and progress in advancing novel discoveries to potential therapeutic applications.

StemCells, Inc. is pleased to be an integral part of this important and rapidly growing event and to have the opportunity to interact with researchers, clinicians, and patients with an interest in novel stem cell-based approaches to intractable neurodegenerative diseases.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

StemCells, Inc. Appoints Dr. Alan Trounson
Company announces appointment of Dr. Trounson to its Board of Directors.
Thursday, July 10, 2014
StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry AMD Trial
Phase II clinical trial to begin this year.
Tuesday, June 24, 2014
StemCells, Inc. Strengthens Senior Executive Team
Company appoints Joel Naor, Naymisha Patel and Mohammad A. El-Kalay and promote Stephen Huhn to the position of vice president.
Thursday, June 19, 2014
StemCells Inc. Advances Clinical Trial in AMD to Final Cohort
Phase I/II AMD trial on track to complete enrollment in June.
Saturday, May 24, 2014
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
Mr. Schiffman will join Company’s executive team, effective January 1, 2014.
Friday, November 15, 2013
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision
HuCNS-SC(R) cells (purified human neural stem cells) found to protect host photoreceptors and preserve vision in an animal model of retinal disease.
Monday, January 30, 2012
StemCells, Inc. Announces Closing of Public Offering of Common Stock and Warrants
The company announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit.
Friday, December 23, 2011
Stemcells, Inc. To Present At 2011 Stem Cell Meeting
StemCells, Inc. have announced that Martin McGlynn, President and CEO, will present a business update at the 2011 Forum.
Tuesday, November 29, 2011
World’s First Neural Stem Cell Transplant in Spinal Cord Injury Patient
The transplant surgery was performed by a team of surgeons led by Dr. Raphael Guzman and Dr. K. Min.
Monday, September 26, 2011
Stemcells, Inc. Awarded CIRM Planning Grant to Pursue Preclinical Development of HuCNS-SC Cells for Alzheimer’s Disease
CIRM has approved the Company’s application for a “Disease Team Therapy Development Planning Award.”
Friday, September 02, 2011
StemCells Regains Compliance for Continued NASDAQ Global Market Listing
Company has received notification from The NASDAQ stock market that the Company has regained compliance with the minimum bid price requirement.
Friday, July 22, 2011
Stemcells, Inc. Relocates Corporate Headquarters and U.S. Research Labs
Corporate headquarters and U.S.-based research and development operations relocate to 7707 Gateway Blvd, Newark, CA 94560, USA.
Wednesday, July 20, 2011
Stemcells to Present Clinical Evidence of Long-term Survival of HuCNS-SC® Cells Following Completion of Immunosuppression Regimen
The data will be reported at the International Society for Stem Cell Research (ISSCR) 9th Annual Meeting, June 15-18 in Toronto, Ontario.
Thursday, June 16, 2011
Scientific News
Controlling DNA Repair
Scientists discover that DNA repair outcomes following CRISPR-Cas9 cleaving are non-random and can be harnessed to produce desired effects.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Challenging Stem Cell Fate Control
Researchers have found that the fate of stem cells is not only controlled by their local niche, but also by a cell-intrinsic mechanism.
Zika Proteins Responsible for Microcephaly Identified
Researchers have undertaken the first study to examine Zika infection in human neural stem cells from second-trimester fetuses.
Heart Muscle from Stem Cells Aid Cardiovascular Medicine
Researchers discover heart muscle cells from stem cells mirror expression patterns of key genes in donor tissue.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
Bone Marrow Transplants Without Using Chemotherapy
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!